Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

June 15, 2018: By Jon Swedien

Optovue’s AngioAnalytics has received US FDA 510(k) clearance, the Fremont, California, company announced June 11.

AngioAnalytics is the world’s first optical coherence tomography angiography (OCTA) blood vessel measurement technology, Optovue said.

Optovue also received FDA clearance for its three-dimensional projection artifact removal (3D PAR) software.

Both AngioAnalytics and 3D PAR are commercially available in the US.

Together, AngioAnalytics and Optovue’s AngioVue OCTA can create color-encoded maps of the vessel densities of the retina or optic nerve, plus provide analysis of areas where there is blood vessel loss (non-perfusion) or abnormal blood vessel growth (flow area). In addition, it offers parameters to assess change to the foveal avascular zone, an area of the retina profoundly affected by diabetic retinopathy.

The new AngioAnalytics software also provides trend analysis so physicians can objectively monitor retinal and vascular changes caused by disease progression or treatment.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility